Skip to main content

Advertisement

SpringerLink
Log in

Medulloblastomas and central nervous system primitive neuroectodermal tumors

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Significant advances in the treatment of medulloblastoma and primitive neuroectodermal tumors have been made in the past three decades. Maximal surgical resection is a mainstay of therapy. However, unlike many other central nervous system neoplasms, medulloblastoma and primitive neuroectodermal tumors are radiation and chemotherapy responsive. Despite this response, the prognosis for patients with these tumors remains variable and is relatively poor in infants and patients with metastatic disease. These tumors most commonly arise in children, thus most clinical trials emphasize the reduction of long-term sequelae, in addition to improving survival. All newly diagnosed patients who are eligible should be offered participation in a clinical trial. If a patient is ineligible or declines consent/ assent for a clinical trial, the best current treatment approach is surgical resection, followed by radiation therapy (except for children younger than 3 years) with weekly vincristine. For high-risk patients, 36 Gy of craniospinal irradiation should be delivered plus a boost of 19.8 Gy to the posterior fossa/primary tumor bed and sites of bulk metastatic disease. For average-risk patients, the craniospinal irradiation dose may be lowered to 23.4 Gy plus 32.4 Gy to the posterior fossa/tumor bed. After radiation therapy, intensive multimodal chemotherapy should be used for all patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Kleihues P, Cavenee WK: Pathology and Genetics of Tumors of the Nervous System. World Health Organization Classification of Tumours. Lyon: IARC Press; 2000.

    Google Scholar 

  2. Pomeroy SL, Tamayo P, Gaasenbeek M, et al.: Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002, 415:436–442. A superb study that analyzes tumor DNA by microarray gene analysis. The results provide insight into the molecular biology of CNS embryonal tumors, prediction of clinical outcome based on gene expression, and potential therapeutic targets. In the future, this technology will likely replace clinical staging for many tumors, including MB/PNET.

    Article  PubMed  CAS  Google Scholar 

  3. McNeil DE, Cote TR, Clegg L, Rorke LB: Incidence and trends in pediatric malignancies medulloblastoma/ primitive neuroectodermal tumor: a SEER update. Med Pediatr Oncol 2002, 39:190–194.

    Article  PubMed  Google Scholar 

  4. Strother DR, Pollack IF, Fisher PG, et al.: Tumors of the central nervous system. In Principles and Practice of Pediatric Oncology. Edited by Pizzo PA, Poplack DG. Philadelphia: Lippincott Williams & Wilkins, 2002:751–824.

    Google Scholar 

  5. Zeltzer PM, Boyett JM, Finlay JL, et al.: Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 1999, 17:832–845.

    PubMed  CAS  Google Scholar 

  6. Reddy AT, Janss AJ, Phillips PC, et al.: Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. Cancer 2000, 88:2189–2193.

    Article  PubMed  CAS  Google Scholar 

  7. Packer RJ: Childhood medulloblastoma: progress and future challenges. Brain Dev 1999, 21:75–81.

    Article  PubMed  CAS  Google Scholar 

  8. Freeman CR, Taylor RE, Kortmann RD, Carrie C: Radiotherapy for medulloblastoma in children: a perspective on current international clinical research efforts. Med Pediatr Oncol 2002, 39:99–108. A recent well-written review on the use of radiation therapy (and chemotherapy) for medulloblastoma in children.

    Article  PubMed  Google Scholar 

  9. Packer RJ, Goldwein J, Nicholson HS, et al.: Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children's Cancer Group study. J Clin Oncol 1999, 17:2127–2136. An important study that showed chemotherapy allows reduced-dose craniospinal radiation therapy in children with average-risk medulloblastoma.

    PubMed  CAS  Google Scholar 

  10. Grotzer MA, Janss AJ, Fung K, et al.: TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol 2000, 18:1027–1035.

    PubMed  CAS  Google Scholar 

  11. Meacham LR, Mazewski C, Krawiecki N: Mechanism of transient adrenal insufficiency with megestrol acetate treatment of cachexia in children with cancer. J Pediatr Hematol Oncol 2003, 25:414–417.

    Article  PubMed  Google Scholar 

  12. McEvoy GK: American Hospital Formulary Service Drug Information. Bethesda: American Society of Health-System Pharmacists; 2002.

    Google Scholar 

  13. Pediatric Brain Tumor Foundation of the United States: http://www.pbtfus.org. Accessed June 7, 2003.

  14. Childhood Brain Tumor Foundation: http:// www.childhoodbraintumor.org. Accessed June 7, 2003.

  15. National Brain Tumor Foundation: http://www.brain-tumor. org. Accessed June 7, 2003.

  16. American Brain Tumor Association: http:// www.abta.org. Accessed June 7, 2003.

  17. Brain Tumor Society: http://www.tbts.org. Accessed June 7, 2003.

  18. American Cancer Society: http://www.cancer.org. Accessed June 7, 2003.

  19. Sutton LN, Phillips PC, Molloy PT: Surgical management of medulloblastoma. J Neurooncol 1996, 29:9–21.

    Article  PubMed  CAS  Google Scholar 

  20. Siffert J, Poussaint TY, Goumnerova LC, et al.: Neurological dysfunction associated with postoperative cerebellar mutism. J Neurooncol 2000, 48:75–81.

    Article  PubMed  CAS  Google Scholar 

  21. Meyers SP, Wildenhain SL, Chang JK, et al.: Postoperative evaluation for disseminated medulloblastoma involving the spine: contrast-enhanced MR findings, CSF cytologic analysis, timing of disease occurrence, and patient out-comes. Am J Neuroradiol 2000, 21:1757–1765.

    PubMed  CAS  Google Scholar 

  22. Takemoto CK, Hodding JH, Kraus DM: Pediatric Dosage Handbook. Hudson: Lexi-Comp, Inc.; 2002.

    Google Scholar 

  23. Ellison DW, Clifford SC, Gajjar A, Gilbertson RJ: What's new in neuro-oncology? Recent advances in medullo-blastoma. Eur J Paediatr Neurol 2003, 7:53–66. A comprehensive review of medulloblastoma, including recent advances in histopathology, molecular genetics, and current and future therapies.

    Article  PubMed  Google Scholar 

  24. Kun LE: Medulloblastoma: challenges in radiation therapy and the addition of chemotherapy. Int J Radiat Oncol Biol Phys 2000, 46:261–263.

    Article  PubMed  CAS  Google Scholar 

  25. Taylor RE, Bailey CC, Robinson K, et al.: Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medullo-blastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 study. J Clin Oncol 2003, 21:1581–1591. This European study is the first large multicenter randomized trial to show that chemotherapy benefits children with non-metastatic medulloblastoma.

    Article  PubMed  CAS  Google Scholar 

  26. del Charco JO, Bolek TW, McCollough WM, et al.: Medulloblastoma: time-dose relationship based on a 30-year review. Int J Radiat Oncol Biol Phys 1998, 42:147–154.

    Article  PubMed  Google Scholar 

  27. Paulino AC, Wen BC, Mayr NA, et al.: Protracted radiotherapy treatment duration in medulloblastoma. Am J Clin Oncol 2003, 26:55–59.

    Article  PubMed  Google Scholar 

  28. Walter AW, Mulhern RK, Gajjar A, et al.: Survival and neurodevelopmental outcome of young children with medulloblastoma at St. Jude Children's Research Hospital. J Clin Oncol 1999, 17:3720–3728.

    PubMed  CAS  Google Scholar 

  29. Ris MD, Packer R, Goldwein J, et al.: Intellectual out-come after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study. J Clin Oncol 2001, 19:3470–3476.

    PubMed  CAS  Google Scholar 

  30. Kortmann RD, Kuhl J, Timmermann B, et al.: Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys 2000, 46:269–279.

    Article  PubMed  CAS  Google Scholar 

  31. Strother D, Ashley D, Kellie SJ, et al.: Feasibility of four consecutive high-dose chemotherapy cycles with stem cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuro-ectodermal tumor after craniospinal radiotherapy: results of a collaborative study. J Clin Oncol 2001, 19:2696–2704.

    PubMed  CAS  Google Scholar 

  32. Yock TI, Friedman H, Kun L, et al.: Response to preradiation chemotherapy is predictive of improved survival in high-risk medulloblastoma: results from Pediatric Oncology Group (POG) 9031 [abstract]. Int J Radiat Oncol Biol Phys 2001, 51(Suppl 1):120–121.

    Article  Google Scholar 

  33. Kellie SJ, Wong CK, Pozza LD, et al.: Activity of postoperative carboplatin, etoposide, and high-dose methotrexate in pediatric CNS embryonal tumors: results of a phase II study in newly diagnosed children. Med Pediatr Oncol 2002, 39:168–174.

    Article  PubMed  Google Scholar 

  34. Turner CD, Gururangan S, Eastwood J, et al.: Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro-oncol 2002, 4:102–108.

    Article  PubMed  CAS  Google Scholar 

  35. Dunkel IJ, Finlay JL: High-dose chemotherapy with autologous stem cell rescue for brain tumors. Crit Rev Oncol Hematol 2002, 41:197–204.

    Article  PubMed  Google Scholar 

  36. Noel G, Habrand JL, Helfre S, et al.: Proton beam therapy in the management of central nervous system tumors in childhood: the preliminary experience of the Centre de Protontherapie d'Orsay. Med Pediatr Oncol 2003, 40:309–315.

    Article  PubMed  Google Scholar 

  37. MacDonald TJ, Brown KM, LaFleur B, et al.: Expression profiling of medulloblastoma: PDGFRA and the RAS/ MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001, 29:143–152.

    Article  PubMed  CAS  Google Scholar 

  38. Packer RJ: Alternative treatments for childhood brain tumors. Childs Nerv Syst 1999, 15:789–794.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Wake Forest University School of Medicine, Medical Center Boulevard, 27157, Winston-Salem, NC, USA

    Thomas W. McLean MD

Authors
  1. Thomas W. McLean MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

McLean, T.W. Medulloblastomas and central nervous system primitive neuroectodermal tumors. Curr. Treat. Options in Oncol. 4, 499–508 (2003). https://doi.org/10.1007/s11864-003-0050-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-003-0050-7

Keywords

Search

Navigation